Anagliptin-d7

Anagliptin-d7 (SK-0403-d7) is deuterium labeled Anagliptin. Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively[1].

Product Specifications

Product Name Alternative

SK-0403-d7

UNSPSC

12352005

Target

Dipeptidyl Peptidase; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Smiles

O=C(NCC(NCC(N1[C@](C([2H])([2H])C([2H])([2H])C1([2H])[2H])([2H])C#N)=O)(C)C)C2=CN3C(N=C2)=CC(C)=N3

Molecular Formula

C19H18D7N7O2

Molecular Weight

390.49

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kato N, et al. Discovery and pharmacological characterization of N-[2- ({2-[ (2S) -2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino) -2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem. 2011 Dec 1;19 (23) :7221-7.|[3]Ervinna N, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013 Mar;154 (3) :1260-70.|[4]Yano W, et al. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. J Diabetes Investig. 2017 Mar;8 (2) :155-160.